Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French medical staff walk out as others turn back:

This article was originally published in Clinica

Executive Summary

While French ultrasound technicians return to work they are seeing many of their colleagues walk out. Medical professionals took action on January 23 to protest against understaffing caused by the application of the 35-hour working week law. This has been aggravated by an influx of patients who cannot see their GPs because they too are on strike. Tensions between general practitioners and the national medical insurance association, the CNAM, over raising the amount GPs can charge for consultations and visits to patients, have forced the GPs to strike and threaten to leave their public sector contracts and go private. There are risks on both sides if there is a mass departure from the public sector, so there are tricky negotiations ahead for both sides.

You may also be interested in...



OTC Codeine Is 'Safe And Effective' – UK Industry Responds To BBC Exposé

Will the UK follow other countries and reverse-switch codeine to prescription-only status? British industry association, the PAGB, responds to a BBC documentary questioning the safety and efficacy of OTC codeine.

French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.

Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

Topics

UsernamePublicRestriction

Register

MT064380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel